论文部分内容阅读
目的 评价在 β受体阻滞剂治疗慢性充血性心力衰竭 (CHF)中脑利钠肽 (BNP)检测意义。方法 选择CHF、心功能Ⅱ～Ⅲ级 (NYHA)患者 33例 ,年龄 19～ 76岁 ,平均 (5 7 5± 15 8)岁。检测房利钠肽 (ANP)、BNP后 ,将其分基础治疗组 12例 (血管紧张素转换酶抑制剂、利尿剂、地高辛 ) ,美托洛尔组 10例 (基础治疗 +美托洛尔 ) ,卡维地洛组 11例 (基础治疗 +卡维地洛 ) ,接受抗心力衰竭 (心衰 )治疗 ,并在治疗 3个月后重复检测ANP、BNP。ANP用放免法 (RIA)测定 ,BNP采用固相免疫放射测定法 (IRMA)测定。结果 心衰有效治疗后ANP、BNP均有显著下降 ,其中 β受体阻滞剂治疗组BNP下降最显著。结论 在评价心衰接受 β受体阻滞剂的治疗反应中BNP具有重要的应用价值。
Objective To evaluate the significance of detecting brain natriuretic peptide (BNP) in β-blocker therapy for chronic congestive heart failure (CHF). METHODS: Thirty-three patients with NYHA were enrolled in this study. The patients were aged from 19 to 76 years (mean, 5 7 5 ± 15 8). Atrial natriuretic peptide (ANP) and BNP were detected in 12 patients (angiotensin converting enzyme inhibitor, diuretic, digoxin) and metoprolol in 10 patients Lol), carvedilol group (basic treatment + carvedilol), and received anti-heart failure (HF) treatment. ANP and BNP were repeated 3 months after treatment. ANP was determined by radioimmunoassay (RIA) and BNP by solid phase immunoradioassay (IRMA). Results ANP and BNP decreased significantly after effective treatment of heart failure, and the decline of BNP in β-blocker treatment group was the most significant. Conclusion BNP plays an important role in evaluating the therapeutic response of heart failure to beta-blocker therapy.